An oral
prostaglandin E1 (
PGE1) analogue, OP-1206.alpha-CD, was given to rats with
streptozocin (STZ)-induced diabetes to examine the
therapeutic effects of
OP-1206 on short-term and long-term
diabetic neuropathy and its action mechanism with special reference to nerve Na(+)-K(+)-
ATPase activity. In the short-term experiment,
OP-1206 was administered daily to diabetic rats in 3- and 30-mg/kg doses for 4 wk from the day of STZ injection. In the long-term study, 10 micrograms/kg
OP-1206 was also given daily for 8 wk from 7 mo after induction of diabetes. The compound improved decreased sciatic motor nerve conduction velocity in both short-term and long-term diabetic rats. The nerve Na(+)-K(+)-
ATPase activity of diabetic rats, reduced by 40% compared with controls, was reversed to the level of controls in both experiments, whereas
weight loss and
hyperglycemia were unchanged, and neither nerve
sorbitol accumulation nor myo-
inositol depletion was corrected. In a morphometric analysis of myelinated nerve fibers (MNFs) in long-term diabetes, the mean diameter of the largest 10% of MNFs was significantly reduced in untreated diabetic compared with control rats, but
OP-1206 completely reversed this reduction. The results suggest that
OP-1206 ameliorates a decrease in nerve Na(+)-K(+)-
ATPase activity without any effect on nerve myo-
inositol level and that the compound may be not only a potent therapeutic agent for the treatment of
diabetic neuropathy but also a useful research tool to investigate the mechanism of nerve Na(+)-K(+)-
ATPase activity regulation.